Polycystic ovary syndrome (PCOS) is known as the most common endocrine disorder in women. Previously, we suggested that human mesenchymal stem cells (MSCs) can reverse the PCOS condition by secreting factors. Here, we evaluated the therapeutic capability of MSC-derived extracellular vesicles (EVs), also known as exosomes, in both in vitro and in vivo PCOS models. Exosomes were used to treat androgen-producing H293R cells and injected in a mouse model through intraovarian and intravenous injection into a letrozole (LTZ)-induced PCOS mouse model. We assessed the effects of the exosomes on androgen-producing cells or the PCOS mouse model by analyzing steroidogenic gene expression (quantitative real-time polymerase chain reaction (qRT–PCR)), body weight change, serum hormone levels, and fertility by pup delivery. Our data show the therapeutic effect of MSC-derived EVs for reversing PCOS conditions, including fertility issues. Interestingly, intravenous injection was more effective for serum glucose regulation, and an intraovarian injection was more effective for ovary restoration. Our study suggests that MSC-derived exosomes can be promising biopharmaceutics for treating PCOS conditions as a novel therapeutic option. Despite the fact that we need more validation in human patients, we may evaluate this novel treatment option for PCOS with the following clinical trials.
Pregnancies following Assisted Reproductive Technology (ART) are associated with increased risk for adverse maternal and neonatal outcomes. However, it is not clear if these associations are derived from infertility or fertility treatment itself. The goal of this review is to investigate if there are differences in maternal and neonatal outcomes between pregnancies conceived through either intrauterine insemination (IUI) or in vitro fertilization (IVF) to obtain an estimate of the effect of the fertility treatment. We retrospectively reviewed the literature for original studies comparing maternal and neonatal outcomes in pregnancies following IUI to those following IVF. To reduce confounding, our synthesis focuses on singleton gestations, while excluding donor sperm and multifetal pregnancies. Findings are interpreted alongside recent ART vs. non-ART evidence to contextualize potential treatment-related effects. Most studies suggest no difference in maternal outcomes, but outcomes were inconsistently reported between studies. Neonatal outcomes were more consistently reported, and there was less variation between results. Current evidence does not suggest a large difference in neonatal outcomes between IVF and IUI. However, almost all studies have significant limitations that hinder clear conclusions. To summarize, even though the current literature does not suggest significant differences in maternal and neonatal outcomes following IVF and IUI, further high-quality studies are needed to establish a definite correlation.